Random effect, variance (SE) | | | | | |
Physician | 0.96 (0.023) | 0.95 (0.022) | 0.91 (0.011) | 0.78 (0.019) | 0.76 (0.019) |
Fixed effects, OR (95% CI) | | | | | |
Constant term | 0.27 (0.26–0.27) | 0.35 (0.34–0.36) | 0.18 (0.17–0.18) | 0.10 (0.09–0.11) | 0.10 (0.08–0.12) |
Year (reference: 2005) | | | | | |
• 2006 | | 0.93 (0.91–0.95) | 0.94 (0.92–0.96) | 0.91 (0.88–0.93) | 0.90 (0.88–0.92) |
• 2007 | | 0.89 (0.87–0.91) | 0.93 (0.91–0.95) | 0.88 (0.86–0.90) | 0.87 (0.85–0.89) |
• 2008 | | 0.85 (0.83–0.87) | 0.92 (0.90–0.94) | 0.87 (0.85–0.89) | 0.86 (0.84–0.88) |
• 2009 | | 0.58 (0.57–0.60) | 0.61 (0.60–0.63) | 0.58 (0.56–0.59) | 0.57 (0.56–0.59) |
• 2010 | | 0.76 (0.74–0.78) | 0.92 (0.90–0.94) | 0.83 (0.81–0.86) | 0.83 (0.81–0.85) |
• 2011 | | 0.75 (0.73–0.77) | 0.94 (0.92–0.96) | 0.86 (0.83–0.88) | 0.85 (0.82–0.87) |
Season (reference: Jun–Aug) | | | | | |
• Mar–May | | 0.98 (0.97–1.00) | 0.99 (0.97–1.00) | 1.05 (1.03–1.07) | 0.99 (0.97–1.02) |
• Sep–Nov | | 0.80 (0.79–0.82) | 0.80 (0.79–0.82) | 0.86 (0.85–0.88) | 0.80 (0.77–0.82) |
• Dec–Feb | | 0.99 (0.97–1.00) | 0.96 (0.94–0.98) | 1.06 (1.04–1.09) | 0.95 (0.92–0.98) |
Patient sex (reference: male) | | | | | |
• Female | | | 0.97 (0.96–0.98) | 0.97 (0.96–0.98) | 0.97 (0.96–0.98) |
Patient age (per y increase) | | | 1.08 (1.08–1.08) | 1.08 (1.08–1.08) | 1.08 (1.08–1.08) |
Follow-up RTI visit | | | 0.98 (0.96–1.01) | 0.97 (0.95–1.00) | 0.97 (0.95–1.00) |
QAIPPE (reference: 1) | | | | | |
• 2 | | | 1.00 (0.98–1.02) | 1.00 (0.98–1.02) | 1.00 (0.98–1.02) |
• 3 | | | 1.01 (0.99–1.03) | 1.01 (0.99–1.03) | 1.01 (0.99–1.03) |
• 4 | | | 1.02 (1.00–1.04) | 1.02 (1.00–1.05) | 1.02 (1.00–1.04) |
• 5 | | | 1.03 (1.01–1.05) | 1.04 (1.02–1.06) | 1.04 (1.02–1.06) |
Diabetes | | | 1.08 (0.95–1.22) | 1.05 (0.93–1.19) | 1.05 (0.93–1.19) |
Asthma | | | 1.06 (1.04–1.08) | 1.06 (1.04–1.08) | 1.06 (1.04–1.08) |
Cystic fibrosis | | | 0.96 (0.80–1.16) | 0.97 (0.80–1.18) | 0.97 (0.80–1.18) |
Immune deficiency | | | 0.92 (0.80–1.07) | 0.92 (0.79–1.06) | 0.92 (0.79–1.06) |
Chronic liver disease | | | 1.07 (0.74–1.56) | 1.03 (0.70–1.52) | 1.00 (0.68–1.48) |
Congestive heart failure | | | 1.30 (0.88–1.92) | 1.12 (0.75–1.69) | 1.12 (0.74–1.68) |
COPD | | | 0.87 (0.78–0.98) | 1.14 (1.02–1.29) | 1.15 (1.02–1.29) |
Chronic kidney disease | | | 0.90 (0.72–1.13) | 1.12 (0.89–1.40) | 1.12 (0.90–1.40) |
Recent antibiotic use | | | 0.85 (0.83–0.87) | 0.86 (0.84–0.88) | 0.86 (0.84–0.88) |
ADG sum | | | 0.97 (0.97–0.97) | 0.97 (0.97–0.97) | 0.97 (0.97–0.97) |
Visits in past 3 y with this physician, % (reference: > 30) | | | | | |
• 0 | | | 1.20 (1.18–1.22) | 1.21 (1.19–1.24) | 1.21 (1.19–1.24) |
• ≤ 30 (but > 0) | | | 1.07 (1.05–1.09) | 1.07 (1.05–1.09) | 1.07 (1.05–1.09) |
No. of different GPs seen in past 3 y | | | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) | 1.02 (1.02–1.02) |
Physician sex (reference: male) | | | | | |
• Female | | | | 0.89 (0.84–0.94) | 0.91 (0.86–0.96) |
Specialty (reference: GP) | | | | | |
• Emergency medicine physician | | | | 0.79 (0.61–1.02) | 0.79 (0.62–1.02) |
• Pediatrician | | | | 0.47 (0.41–0.55) | 0.48 (0.42–0.56) |
• Other | | | | 0.88 (0.72–1.06) | 0.89 (0.73–1.07) |
Visits for RTIs in the past 30 d, % (reference: > 20) | | | | | |
• None | | | | 1.34 (1.21–1.49) | 1.36 (1.23–1.51) |
• ≤ 2.5 | | | | 1.42 (1.35–1.49) | 1.45 (1.38–1.52) |
• > 2.5–5 | | | | 1.40 (1.34–1.45) | 1.42 (1.36–1.48) |
• > 5–7.5 | | | | 1.32 (1.27–1.37) | 1.33 (1.29–1.38) |
• > 7.5–10 | | | | 1.25 (1.21–1.30) | 1.26 (1.22–1.31) |
• > 10–15 | | | | 1.21 (1.17–1.25) | 1.22 (1.18–1.25) |
• > 15–20 | | | | 1.13 (1.10–1.16) | 1.13 (1.10–1.16) |
Medical school graduation location (reference: Canada) | | | | | |
• International | | | | 1.77 (1.68–1.88) | 1.73 (1.63–1.83) |
Daily patient volume (reference: 1st quartile [< 28 visits]) | | | | | |
• 2nd quartile (28–37 visits) | | | | 0.99 (0.97–1.01) | 0.99 (0.98–1.01) |
• 3rd quartile (38–48 visits) | | | | 0.97 (0.95–0.99) | 0.97 (0.95–0.99) |
• 4th quartile (> 48 visits) | | | | 0.94 (0.92–0.96) | 0.94 (0.92–0.97) |
Years since medical school graduation (reference: 0–5) | | | | | |
• 6–10 | | | | 0.98 (0.93–1.03) | 0.99 (0.94–1.04) |
• 11–15 | | | | 1.07 (1.01–1.14) | 1.08 (1.02–1.15) |
• 16–20 | | | | 1.15 (1.08–1.22) | 1.16 (1.09–1.24) |
• 21–25 | | | | 1.21 (1.13–1.29) | 1.23 (1.15–1.31) |
• 26–30 | | | | 1.29 (1.21–1.39) | 1.32 (1.23–1.41) |
• 31–35 | | | | 1.32 (1.23–1.42) | 1.35 (1.26–1.46) |
• 36–40 | | | | 1.36 (1.25–1.47) | 1.39 (1.29–1.51) |
• > 40 | | | | 1.41 (1.28–1.56) | 1.46 (1.33–1.61) |
No. of RTIs seen in the past y (reference: 1st quartile [≤ 248]) | | | | | |
• 2nd quartile (249–490) | | | | 1.10 (1.07–1.13) | 1.11 (1.08–1.14) |
• 3rd quartile (491–972) | | | | 1.17 (1.12–1.21) | 1.19 (1.15–1.23) |
• 4th quartile (≥ 973) | | | | 1.27 (1.21–1.33) | 1.31 (1.25–1.37) |
LHA population aged > 65 y (per 10%) | | | | | 0.99 (0.98–1.00) |
LHA population aged < 15 y (per 10%) | | | | | 1.12 (1.06–1.17) |
Median age of LHA population (centred on mean) | | | | | 1.19 (1.11–1.27) |
Health authority (reference: Vancouver Coastal) | | | | | |
• Interior | | | | | 1.07 (1.02–1.13) |
• Fraser | | | | | 1.00 (0.97–1.03) |
• Vancouver Island | | | | | 1.03 (0.98–1.08) |
• Northern | | | | | 1.20 (1.13–1.28) |
28-d moving average apparent temperature | | | | | 0.99 (0.99–0.99) |